Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).

被引：9
|
作者：
Khozin, Sean
Walker, Mark S.
Jun, Monika
Chen, Li
Stepanski, Edward
Rubinstein, Wendy S.
Komatsoulis, George Anthony
Roberts, Jeremy
Zhi, Jizu
Miller, Robert S.
Fukushima, Ryan
Lau, Denise
Hyde, Brigham
机构：
[1] US FDA, Silver Spring, MD USA
[2] ACORN Res LLC, Memphis, TN USA
[3] Concerto HealthAI, Boston, MA USA
[4] Amer Soc Clin Oncol ASCO CancerLinQ, Alexandria, VA USA
[5] Tempus, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.110
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
110
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor.
    Khozin, Sean
    Zhi, Jizu
    Jun, Monika
    Chen, Li
    Rubinstein, Wendy S.
    Walker, Mark S.
    Komatsoulis, George Anthony
    Roberts, Jeremy
    Fukushima, Ryan
    Lau, Denise
    Hyde, Brigham
    Stepanski, Edward
    Miller, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Sequencing of ramucirumab (ram) and immune checkpoint inhibitors (ICIs) in platinum (Pt)-treated real-world patients (pts) with advanced non-small cell lung cancer (aNSCLC)
    Clarke, Jeffrey Melson
    Molife, Cliff
    Miksad, Rebecca
    Batus, Marta
    Winfree, Katherine B.
    Gossai, Anala
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AFTER INTRODUCTION OF IMMUNE CHECKPOINT INHIBITORS (ICIS) IN PATIENTS WITH ADVANCED/ METASTATIC NON-SMALL CELL LUNG CANCER (ANSCLC) IN EUROPE (EU4+UK)
    Slowley, A.
    Kalilani, L.
    Multani, J.
    Casey, V
    Mpima, S.
    Yasuda, M.
    Chen, C. C.
    Manuguid, F.
    Chao, J.
    Aziez, A.
    Bell, K.
    Stojadinovic, A.
    VALUE IN HEALTH, 2022, 25 (12) : S277 - S277
  • [4] Real-World Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US
    Nadler, E.
    Chang, J.
    Zhang, X.
    Aguilar, K.
    Zhou, J.
    Arondekar, B.
    Pawar, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S38 - S39
  • [5] Immune checkpoint inhibitors in advanced non-small cell lung cancer: Real-world survival and safety
    Tang, Monica
    Lee, Chee
    Lewis, Craig
    Boyer, Michael
    Brown, Bernadette
    Schaffer, Andrea
    Pearson, Sallie-Anne
    Simes, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 30 - 31
  • [6] Real-world use and survival outcomes of immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Youn, Bora
    Trikalinos, Nikolaos
    Mor, Vincent
    Wilson, Ira
    Dahabreh, Issa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Real-world treatment sequencing in advanced non-small cell lung cancer (aNSCLC).
    Radtchenko, Janna
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] IDENTIFYING GENETIC FACTORS FOR RESISTANCE AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS (ICIS) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS USING REAL-WORLD DATA
    Singh, Neeraj
    Agrawal, Smita
    Narayanan, Babu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A557 - A557
  • [9] REAL-WORLD TREATMENT (TX) CHARACTERISTICS FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) WITHOUT ACTIONABLE MUTATIONS AFTER INTRODUCTION OF IMMUNE CHECKPOINT INHIBITORS (ICIS) IN EU4 AND UK
    Multani, J.
    Casey, V
    Mpima, S.
    Yasuda, M.
    Chen, C. C.
    Manuguid, F.
    Kalilani, L.
    Giove, T. J.
    Chao, J.
    Aziez, A.
    Stojadinovic, A.
    Hogea, C.
    VALUE IN HEALTH, 2022, 25 (01) : S154 - S155
  • [10] Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer
    Wan, R.
    Duan, J.
    Wang, Z.
    Lin, L.
    Li, W.
    Jie, W.
    ANNALS OF ONCOLOGY, 2022, 33 : S54 - S54
12345